{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T19:46:07Z","timestamp":1793389567487,"version":"4.5.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,10,13]],"date-time":"2016-10-13T00:00:00Z","timestamp":1476316800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["1005"],"award-info":[{"award-number":["1005"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1007\/s00277-016-2826-4","type":"journal-article","created":{"date-parts":[[2016,10,13]],"date-time":"2016-10-13T02:02:03Z","timestamp":1476324123000},"page":"87-92","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Management of extreme thrombocytosis in myeloproliferative neoplasms: an international physician survey"],"prefix":"10.1007","volume":"96","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7223-328X","authenticated-orcid":false,"given":"Maya","family":"Koren-Michowitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noa","family":"Lavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin H.","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro M.","family":"Vannucchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Mesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire N.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,10,13]]},"reference":[{"key":"2826_CR1","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1055\/s-0034-1370794","volume":"40","author":"A Falanga","year":"2014","unstructured":"Falanga A, Marchetti M (2014) Thrombosis in myeloproliferative neoplasms. Semin Thromb Hemost 40:348\u2013358","journal-title":"Semin Thromb Hemost"},{"key":"2826_CR2","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/ajh.23895","volume":"90","author":"A Tefferi","year":"2015","unstructured":"Tefferi A, Barbui T (2015) Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management. Am J Hematol 90:162\u2013173","journal-title":"Am J Hematol"},{"key":"2826_CR3","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1182\/blood-2014-07-591610","volume":"124","author":"T Barbui","year":"2014","unstructured":"Barbui T, Carobbio A, Rumi E et al (2014) In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology. Blood 124:3021\u20133023","journal-title":"Blood"},{"key":"2826_CR4","doi-asserted-by":"crossref","first-page":"5857","DOI":"10.1182\/blood-2011-02-339002","volume":"117","author":"A Carobbio","year":"2011","unstructured":"Carobbio A, Thiele J, Passamonti F et al (2011) Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood 117:5857\u20135859","journal-title":"Blood"},{"key":"2826_CR5","doi-asserted-by":"crossref","first-page":"5128","DOI":"10.1182\/blood-2012-07-444067","volume":"120","author":"T Barbui","year":"2012","unstructured":"Barbui T, Finazzi G, Carobbio A et al (2012) Development and validation of an International Prognostic Score of thrombosis in World Health Organization\u2013essential thrombocythemia (IPSET-thrombosis). Blood 120:5128\u20135133","journal-title":"Blood"},{"key":"2826_CR6","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1182\/blood-2014-08-596676","volume":"124","author":"G Finazzi","year":"2014","unstructured":"Finazzi G, Carobbio A, Guglielmelli P et al (2014) Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia. Blood 124:2611\u20132612","journal-title":"Blood"},{"key":"2826_CR7","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1182\/blood-2013-11-539098","volume":"123","author":"E Rumi","year":"2014","unstructured":"Rumi E, Pietra D, Ferretti V et al (2014) JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood 123:1544\u20131551","journal-title":"Blood"},{"key":"2826_CR8","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/leu.2015.277","volume":"30","author":"D Pietra","year":"2016","unstructured":"Pietra D, Rumi E, Ferretti VV et al (2016) Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms. Leukemia 30:431\u2013438","journal-title":"Leukemia"},{"key":"2826_CR9","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","volume":"369","author":"T Klampfl","year":"2013","unstructured":"Klampfl T, Gisslinger H, Harutyunyan AS et al (2013) Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 369:2379\u201390","journal-title":"N Engl J Med"},{"key":"2826_CR10","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1182\/blood-2013-11-538983","volume":"123","author":"G Rotunno","year":"2014","unstructured":"Rotunno G, Mannarelli C, Guglielmelli P et al (2014) Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood 123:1552\u20131555","journal-title":"Blood"},{"key":"2826_CR11","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1182\/blood-2012-10-429134","volume":"121","author":"C Patrono","year":"2013","unstructured":"Patrono C, Rocca B, De Stefano V (2013) Platelet activation and inhibition in polycythemia vera and essential thrombocythemia. Blood 121:1701\u20131711","journal-title":"Blood"},{"key":"2826_CR12","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1182\/asheducation-2011.1.391","volume":"2011","author":"BA Konkle","year":"2011","unstructured":"Konkle BA (2011) Acquired disorders of platelet function. Hematology 2011:391\u2013396","journal-title":"Hematology"},{"key":"2826_CR13","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/leu.2011.258","volume":"26","author":"G Finazzi","year":"2012","unstructured":"Finazzi G, Carobbio A, Thiele J et al (2012) Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria. Leukemia 26:716\u2013719","journal-title":"Leukemia"},{"key":"2826_CR14","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1200\/JCO.2010.31.8436","volume":"29","author":"T Barbui","year":"2011","unstructured":"Barbui T, Barosi G, Birgegard G et al (2011) Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European leukemiaNet. J Clin Oncol 29:761\u2013770","journal-title":"J Clin Oncol"},{"key":"2826_CR15","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1002\/1097-0142(19861201)58:11<2440::AID-CNCR2820581115>3.0.CO;2-Y","volume":"58","author":"S Bellucci","year":"1986","unstructured":"Bellucci S, Janvier M, Tobelem G et al (1986) Essential thrombocythemias clinical evolutionary and biological data. Cancer 58:2440\u20132447","journal-title":"Cancer"},{"key":"2826_CR16","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1182\/blood.V82.6.1749.1749","volume":"82","author":"U Budde","year":"1993","unstructured":"Budde U, Scharf RE, Franke P et al (1993) Elevated platelet count as a cause of abnormal von Willebrand factor multimer distribution in plasma. Blood 82:1749\u20131757","journal-title":"Blood"},{"key":"2826_CR17","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/1097-0142(19900801)66:3<549::AID-CNCR2820660324>3.0.CO;2-6","volume":"66","author":"P Fenaux","year":"1990","unstructured":"Fenaux P, Simon M, Caulier MT et al (1990) Clinical course of essential thrombocythemia in 147 cases. Cancer 66:549\u2013556","journal-title":"Cancer"},{"key":"2826_CR18","doi-asserted-by":"crossref","first-page":"54","DOI":"10.2302\/kjm.37.54","volume":"37","author":"K Sato","year":"1998","unstructured":"Sato K (1998) Plasma von Willebrand factor abnormalities in patients with essential thrombocythemia. Keio J Med 37:54\u201371","journal-title":"Keio J Med"},{"key":"2826_CR19","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1093\/ajcp\/88.1.102","volume":"88","author":"BK Raman","year":"1987","unstructured":"Raman BK, Sawdyk M, Saeed SM (1987) Essential thrombocythemia with acquired von Willebrand\u2019s disease. Am J Clin Pathol 88:102\u2013106","journal-title":"Am J Clin Pathol"},{"key":"2826_CR20","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13045-016-0242-9","volume":"9","author":"A Kaifie","year":"2016","unstructured":"Kaifie A, Kirschner M, Wolf D et al (2016) Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry. J Hematol Oncol 9:18\u201329","journal-title":"J Hematol Oncol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-016-2826-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-016-2826-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-016-2826-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T16:18:56Z","timestamp":1601137136000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-016-2826-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,13]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["2826"],"URL":"https:\/\/doi.org\/10.1007\/s00277-016-2826-4","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,13]]}}}